TrialThe New England journal of medicine2021
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Toni K Choueiri et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
997 papers cite itlatest 60 shown
this paperpooled ittrialcites it